Exendin PET/CT for imaging of paragangliomas

Exendin PET/CT for imaging of paragangliomas - ENTRAP

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50901

Enrollment

Registered

2021-07-26

Start date

2022-11-01

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paraganglioma

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: • Proven PGL with a single tumor detected using standard diagnostic imaging • No evidence of metastatic disease • SSTR PET performed • Scheduled for surgery • Able to sign informed consent

Exclusion criteria

Exclusion criteria: • Breast feeding • Pregnancy or the wish to become pregnant within 1 month • Calculated creatinine clearance below 40ml/min • Evidence of other malignancy than PGL in conventional imaging (suspicious liver, bone and lung lesions) • Age

Design outcomes

Primary

Measure	Time frame
Detection rate of PGLs using 68Ga-exendin-4 PET/CT	—

Secondary

Measure	Time frame
• Optimal timepoint for imaging PGLs using 68Ga-exendin-4 PET/CT. • Comparison of quantitative imaging parameters (SUV, tumor-to-background ratio, contract-to-noise ratio) between 68Ga-exendin-4 PET and SSTR PET. • Correlation between GLP-1R expression and tracer uptake in the PGLs. • Correlation quantitative imaging results and IHC data to the genetic origin of the PGLs.	—

Countries

Netherlands

Outcome results